It is estimated thataround 80% of innovator companies rely on external companion diagnosticdevelopers, mostly owing to the lack of the required in-house expertise. On theother hand, there are numerous contract service providers, offering vastportfolios of services for diagnostic test / assay development. Such companiesare known to possess extensive technical knowledge, and experience in workingwith cutting-edge analytical tools and technologies, such as in situhybridization (ISH), immunohistochemistry (IHC), next generation sequencing(NGS), polymerase chain reaction (PCR).
To order this 320+page report, which features 120+ figures and 115+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html
The USD 800+ million (by 2030) financialopportunity within the companion diagnostics development services market hasbeen analysed across the following segments:
§ Type of Service Offered
- Feasibility Studies
- Assay Development
- Analytical Validation
- Clinical Validation
§ Type of Assay Technique Used
§ in situ hybridization / Immunohistochemistry
§ Next Generation Sequencing
§ Polymerase Chain Reaction
§ Others
§ Keygeographical regions
§ North America
§ Europe
§ Asia Pacific
The report featuresinputs from eminent industry stakeholders, according to whom the development ofcompanion diagnostics is largely outsourced, owing to the exorbitant costsassociated with the setting-up of in-house expertise / capabilities. The reportincludes detailed transcripts of discussions held with the following experts:
§ Anton Iliuk (President and Chief Technology Officer, TymoraAnalytica)
§ Paul Kortschak (Senior Vice President, Novodiax)
§ Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
§ Lawrence M. Weiss (Chief Scientific Officer, NeoGenomicsLaboratories)
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Company Profiles
6. Partnerships and Collaborations
7. Likely Partner Analysis
8. Company Competitiveness Analysis
9. Stakeholder Needs Analysis
10. Value Chain Analysis
11. Clinical Research on Cancer Biomarkers: Big PharmaPerspective
12. Market Forecast And Opportunity Analysis
13. Executive Insights
14. Appendix 1: Tabulated Data
15. Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
